2024-10-15 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets a wide range of biopharmaceutical products.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** 83.62% (AMGN) vs 135.82% (VOO).
* **Relative Lag:** -52.2% (33.78% relative to historical range). 
    *  AMGN has underperformed VOO by a significant margin, with a 52.2% lag in cumulative return. 
    * This lag places AMGN at the 33.78% percentile of its historical relative performance against VOO.

**2. Recent Price Movement:**

* **Closing Price:** $328.35
* **5-Day Moving Average:** $321.38 
* **20-Day Moving Average:** $325.42 
* **60-Day Moving Average:** $327.48

**3. Technical Indicators:**

* **RSI:** 44.49 -  Neutral, indicating neither overbought nor oversold conditions.
* **PPO:** 0.05 -  Slightly positive, suggesting potential for price growth.
* **Delta_Previous_Relative_Divergence:** -9.01 (20-day) - Negative, suggesting recent short-term price weakness.
* **Expected Return:** 0.0% - Currently, the expected return for AMGN is 0% over the next 5 years relative to VOO, indicating a potential for similar performance.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ | 

* **Latest Earnings (2024-08-07):** EPS of $1.39 was higher than expected.
* **Revenue Growth:**  AMGN has consistently shown revenue growth in the last few quarters. 
* **Outlook:** Despite the recent earnings beat, the market remains cautious due to the relative underperformance compared to VOO.

**5. News and Recent Issues:**

* **Recent Market Outlook:** The market remains cautiously optimistic about Amgen's future growth potential. The company has been heavily investing in new drug development, particularly in areas like oncology and cardiovascular disease.
* **Analyst Opinions:** Analysts are mostly bullish on AMGN, citing the strong revenue growth, pipeline potential, and potential for future growth. 
* **Performance Highlights:** Recent performance highlights include the approval of new drugs, increased market share, and cost-cutting measures. 
* **FINBOLD** provides a detailed overview of the company's performance, including key metrics, news updates, and expert opinions.

**6. Overall Analysis:**

Amgen Inc. (AMGN) is a large-cap biotechnology company with a solid track record of revenue growth and a strong pipeline of new drugs. However, the company has lagged behind the broader market in recent years, leading to concerns about its future growth potential. While the company has demonstrated strong recent earnings, the market's overall outlook remains cautious. Investors considering AMGN should monitor the company's progress in developing new drugs, its ability to increase market share, and its competitive position within the biotechnology sector.

**7. Recommendations:**

* **Conservative Investors:**  Due to the recent underperformance and the cautious market outlook, conservative investors may want to wait for further evidence of improvement in AMGN's relative performance.
* **Growth-Oriented Investors:** Growth-oriented investors who believe in AMGN's long-term growth potential may find it attractive at current levels. 
* **Active Traders:** Active traders may find short-term trading opportunities based on AMGN's price action and technical indicators.

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial professional before making any investment decisions.